Nanjing Leads Biolabs Co., Ltd. (HKG:9887)
Hong Kong · Delayed Price · Currency is HKD 54.00
+0.40 (0.75%)
Jun 18, 2026, 4:08 PM HKT
Nanjing Leads Biolabs Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Nanjing Leads Biolabs stock has a consensus rating of "Buy" and an average price target of $95.93. The average 1-year stock price forecast is 77.65% higher than the current stock price, while the lowest is $62.17 (+15.13%) and the highest is $109.91 (+103.54%).
Price Target: $95.93 (+77.65%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Nanjing Leads Biolabs stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Morgan Stanley No rating | Morgan Stanley | Hold Maintains $62.00 | Hold | Maintains | $62.00 | +14.81% | May 28, 2026 |
Unknown Analyst GF Securities No rating | GF Securities | Buy Maintains $110.96 | Buy | Maintains | $110.96 | +105.48% | Apr 28, 2026 |
Unknown Analyst Orient Securities No rating | Orient Securities | Buy Maintains $81.01 → $103.06 | Buy | Maintains | $81.01 → $103.06 | +90.85% | Apr 21, 2026 |
Unknown Analyst Huafu Securities No rating | Huafu Securities | Buy Maintains $101.90 → $140.75 | Buy | Maintains | $101.90 → $140.75 | +160.65% | Apr 15, 2026 |
Andy Wang CMB International Securities No rating | CMB International Securities | Buy Maintains $100.50 | Buy | Maintains | $100.50 | +86.11% | Mar 31, 2026 |
Financial Forecast
Revenue This Year
198.50M
from 177.26M
Increased by 11.99%
Revenue Next Year
483.89M
from 198.50M
Increased by 143.77%
EPS This Year
-0.89
from -1.03
EPS Next Year
-0.57
from -0.89
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 270.0M | ||
| Avg | 198.5M | ||
| Low | 120.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 52.3% | ||
| Avg | 12.0% | ||
| Low | -32.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | -0.89 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |